Navigation Links
GeneTex, Inc. to Launch a New Primary Antibody against HIF1a
Date:8/28/2012

IRVINE, Calif., Aug. 28, 2012 /PRNewswire/ -- GeneTex, Inc., a leading manufacturer of antibodies, has announced that they will be launching a new antibody against HIF1a (hypoxia-inducible factor 1alpha).

(Photo: http://photos.prnewswire.com/prnh/20120828/AQ63427)

(Logo: http://photos.prnewswire.com/prnh/20111129/LA13485LOGO-b)

Hypoxia, a physiological state characterized by reduced oxygen levels, impacts metabolism, angiogenesis, vasodilation and erythropoiesis through the HIF1a transcription factor. In addition to being a natural physiological process, hypoxia and the subsequent accumulation of HIF1a have been shown to significantly contribute to the pathophysiology of multiple diseases including cancer, pulmonary hypertension, myocardial and cerebral ischemia, congenital heart disease and chronic obstructive pulmonary disease. When oxygen becomes limited, prolyl hydroxylase is inhibited, which leads to HIF1a accumulation and translocation to the nucleus. HIF1a then activates transcription of various genes including VEGFA, Glut1 and CA9 that are responsible for the cellular hypoxia response. Therefore, antibodies that can accurately detect HIF1a are valuable research tools for the study of hypoxia and hypoxia-related diseases.

"HIF1a is an important target for biomedical research, but unfortunately many of the antibodies that are currently on the market have been plagued by specificity and stability issues," says Dr. Stephen Kendall. "GeneTex's new HIF1a antibody can withstand multiple freeze/thaw cycles without losing its sensitivity."

GeneTex is proud to introduce this superior antibody against HIF1a that is both highly stable and specific. This antibody has been fully validated for immunocytochemistry/immunofluorescence, immunoprecipitation and western blotting applications. 

For additional information on GeneTex, Inc. and its hypoxia antibodies, please call toll-free 877-GENETEX (436-3839) or visit http://www.genetex.com/HIF1-alpha-antibody-GTX127309.html.

About GeneTex, Inc.
GeneTex, Inc. is an antibody manufacturer founded by a group of internationally renowned academic scientists in 1997. They strive to produce the highest quality antibodies and reagents. Their primary antibodies and secondary antibodies are created through a process involving extensive research, development and validation.  GeneTex's catalog has grown to over 55,000 primary antibodies and all are backed by a 100% Satisfaction Guarantee. 

Corporate Mission
We strive to serve and accelerate life science research by creating essential life science tools where quality can be found in every vial.


'/>"/>
SOURCE GeneTex, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AllMobilityScooters.com Launches Blog
2. Selfhelp Community Services and FEGS Health & Human Services Launch New Care Management Company: SinglePoint Care Network to Coordinate Care for Seniors & Others With Chronic Medical Conditions in Managed Long Term Care Market
3. BioWorld Launches Enhanced Biopharma News Site with Data, Analysis
4. Precision Automation Expert DWFritz Automation Announces Website Launch www.DWFritz.com
5. MGC Diagnostics Corporation Launches New Corporate Website and Unveils New Logo
6. Ranbaxy Launches Authorized Generic Of Pioglitazone In The U.S.
7. Express Scripts Launches Virtual Coaching To Help Patients Better Understand Therapy
8. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Masimo Corporation in Connection with Executive Compensation
9. Omnetics Launches Cable Design for Micro-wire Harnesses in Miniature Electronics
10. Elsevier Launches New Journal: Discourse, Context and Media
11. Mylan Launches Lithium Carbonate Extended-Release Tablets USP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2020)... ... September 01, 2020 , ... Mara C. Weinstein Velez, M.D., ... the University of Rochester Medical Center, in Upstate New York. She completed a ... clinical faculty from the Harvard and Yale Departments of Dermatology and is one ...
(Date:9/1/2020)... ... September 01, 2020 , ... While coronavirus cases continue to increase across the ... community organizations remain closed. Because about 80% of blood donations are made at drives ... donors and blood drive hosts to ensure blood products are readily available for patients. ...
(Date:9/1/2020)... ... September 01, 2020 , ... September is National Ovarian Cancer ... more deaths than any other cancer of the female reproductive system. The American ... cancer and about 14,000 women will die from this disease. Throughout the month ...
Breaking Medicine Technology:
(Date:9/1/2020)... (PRWEB) , ... September 01, 2020 , ... ... it has completed $3 million convertible note financing, which will be used to ... With the funds from this financing, the company will continue to expand its ...
(Date:9/1/2020)... Calif. (PRWEB) , ... September 01, 2020 , ... As ... “safe side”, the Cohn Health Institute has taken this time to expand ... celebration of its 30th Anniversary, the Cohn Health Institute will be relaunching its brand ...
(Date:8/31/2020)... ... 2020 , ... Cardiothoracic surgeons at Allegheny General Hospital (AGH), ... University (CMU) to develop a new heart monitoring device designed to serve as ... The AGH/CMU team was recently awarded a “Trailblazer” grant from the National Institutes ...
(Date:8/31/2020)... ... ... found out your dear friend has cancer? , It’s hard to hear your doctor say ... diagnosis. Once the shock wears off, the questions and fears can be overwhelming. , How ... to help? Words are failing me. I’m scared. I want to DO something. , We’ve ...
(Date:8/31/2020)... ... August 31, 2020 , ... Want to get moving, break up ... Research Foundation (CPARF) is thrilled to launch its fourth annual STEPtember campaign in the ... challenge, STEPtember meets everyone wherever they are at this moment — encouraging people to ...
Breaking Medicine News(10 mins):